文献速递肿瘤 PET/CT核素与放射性配体治疗

中期[18F]FDG PET在大B细胞淋巴瘤中的预后价值:系统评价与Meta分析聚焦Deauville 5分病变

Prognostic Value of Interim [18F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease.
PubMed 文献 · J Nucl Med · 2026-04-01

该系统评价与Meta分析纳入44项研究,评估中期[18F]FDG PET预测大B细胞淋巴瘤治疗结束反应、无进展生存(PFS)和总生存(OS)的价值。结果显示,中期PET阳性(Deauville 4-5分)与不良PFS和OS显著相关,其中Deauville 5分预测价值最高;但中期PET预测治疗结束反应时不能可靠排除或确认治疗结束PET结果。

要点

  • 中期PET阳性(Deauville 4-5分)与PFS HR 2.88及OS HR 3.71显著相关。
  • Deauville 5分对PFS的HR为5.59,对OS的HR为8.10,预测价值高于Deauville 4-5分。
  • 中期PET预测治疗结束反应的汇总敏感度0.78、特异度0.84,但阳性/阴性似然比不可靠。

核心结论

  • Deauville 5分是中期PET预测大B细胞淋巴瘤治疗不良反应的高度可靠指标。
  • 该阈值用于升级或修改治疗需在未来前瞻性试验中评估。

研究设计与样本

  • 系统检索3个主要医学文献数据库至2025年1月8日,纳入44项评估中期PET预后价值的原创研究。
  • 采用分层法合并随机效应模型的敏感度、特异度、阳性似然比和阴性似然比,双变量模型确定95%CI,并合并PFS和OS的生存比例及风险比(HR)。

主要发现

  • 中期PET预测治疗结束反应的汇总敏感度为0.78(95%CI 0.69-0.84),特异度为0.84(95%CI 0.78-0.88)。
  • 基于汇总阳性及阴性似然比,中期PET不能可靠排除或确认治疗结束[18F]FDG PET结果。
  • 所有可用数据集(n=27)中,中期PET阳性(Deauville 4-5分)的汇总PFS HR为2.88(95%CI 2.35-3.52)。
  • 在比较中期PET阳性与单独Deauville 5分的数据集中,汇总PFS HR分别为2.36(95%CI 1.74-3.21)与5.59(95%CI 4.35-7.19)。
  • 所有可用数据集(n=22)中,中期PET阳性的汇总OS HR为3.71(95%CI 2.93-4.69);在比较中期PET阳性与单独Deauville 5分的数据集(n=5)中,汇总OS HR分别为3.31(95%CI 2.09-5.24)与8.10(95%CI 6.04-10.85)。

关键数值与推荐

  • 中期PET阳性定义为Deauville评分4-5分,预测治疗结束反应的汇总敏感度0.78(95%CI 0.69-0.84)、特异度0.84(95%CI 0.78-0.88)。
  • Deauville 5分预测PFS的HR为5.59(95%CI 4.35-7.19),预测OS的HR为8.10(95%CI 6.04-10.85)。
  • 中期PET阳性(Deauville 4-5分)预测PFS的HR为2.88(95%CI 2.35-3.52),预测OS的HR为3.71(95%CI 2.93-4.69)。

临床怎么用

  • 中期PET显示Deauville 5分提示治疗反应不良风险高,可考虑作为预后分层依据。
  • 基于中期PET结果升级或修改治疗策略尚未经前瞻性试验验证,需谨慎。
  • 中期PET不宜单独用于排除或确认治疗结束PET的反应状态。

局限性

  • 原文未报告纳入研究的偏倚风险、异质性来源及发表偏倚评估结果。
  • 关于Deauville 5分与SUVmax变化比较的数据集数量有限(PFS n=6,OS n=5)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our rationale was to investigate the potential of interim [18F]FDG PET (iPET) in predicting large B-cell lymphoma (LBCL) patients' outcomes, including the end-of-treatment response, progression-free survival (PFS), and overall survival (OS). Methods: A systematic search was conducted on the 3 main medical literature databases until January 8, 2025. Published original articles that evaluated iPET for prognosticating LBCL patients and provided crude data for meta-analytic calculations were considered eligible. The hierarchic method was used to pool the random-effect model's end-of-treatment prediction performance measures of sensitivity, specificity, positive likelihood ratio (LR), and negative LR. The bivariate model was used to determine the corresponding 95% CI. Furthermore, PFS and OS were pooled across studies, including survival proportions and hazard ratios (HRs). All analyses were conducted using STATA 16 software. Results: The initial search resulted in 939 studies. After the full-text review, 44 studies were considered eligible. The pooled sensitivity and specificity of iPET for predicting end-of-treatment response were 0.78 (95% CI, 0.69-0.84) and 0.84 (95% CI, 0.78-0.88), respectively. On the basis of the pooled positive and negative LRs, iPET was not a reliable modality to exclude or confirm the end-of-treatment [18F]FDG PET results. The pooled PFS HR across all available datasets (n = 27) was 2.88 (95% CI, 2.35-3.52) for positive iPET (Deauville score [DS] 4-5). In datasets with HRs for positive iPET versus DS 5 alone, the pooled HRs were 2.36 (95% CI, 1.74-3.21) versus 5.59 (95% CI, 4.35-7.19). Furthermore, when datasets were limited to those with data on change in SUVmax versus DS 5 (n = 6), the pooled HRs were 3.41 (95% CI, 2.67-4.35) versus 5.59 (95% CI, 4.35-7.19), respectively. The pooled OS HR across all available datasets (n = 22) was 3.71 (95% CI, 2.93-4.69) for positive iPET. In datasets with HRs for positive iPET versus DS 5 alone (n = 5), the pooled HRs were 3.31 (95% CI, 2.09-5.24) versus 8.10 (95% CI, 6.04-10.85). Moreover, when datasets were limited to those with data on change in SUVmax versus DS 5 (n = 5), the pooled HRs were 4.54 (95% CI, 3.57-5.78) versus 8.10 (95% CI, 6.04-10.85). Conclusion: On the basis of our comprehensive systematic review and meta-analysis, DS 5 is a highly reliable predictor of unfavorable response to therapy on iPET. The utility of this threshold to escalate or modify therapy needs to be evaluated in future prospective trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mirshahvalad SA, Hodgson D, Kuruvilla J, et al. Prognostic Value of Interim [18F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease. J Nucl Med. 2026. PMID: 41545069. doi:10.2967/jnumed.125.271089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。